Assurea serves as a digital implementation and validation unit for fast growing clients
🚀 We are Assurea—a digital compliance consulting firm specializing in IT/CSV services, software assurance, and custom AI solutions. Our consulting model is built around what our clients actually need—no fluff, just real solutions. We serve startups, large-scale projects, and software providers.
🔍Forward-Looking: As Assurea grows, we are committed to expanding our global impact in STEM— solving problems and creating waves of positive change. 🌍✨
At Assurea, We Drive Results!
Service Lines
We always bring the A-Team! Assurea provides fractional services for clinical startups, supports large-scale IT/CSV projects, and helps software providers with certification preparation to meet regulatory standards.Our team of experts is highly skilled and part of the ISPE GAMP Steering Committee, contributing to industry best practices.
Why Assurea?
We always bring the A-Team! Choosing Assurea means partnering with a team that is hyper focused on digital implementations and validation. Organizations work with us when they need a specialized digital implementation partner—not a general consulting firm. We don't try to do everything. We specialize in one thing: helping regulated life sciences organizations successfully implement and validate digital technologies.
Clients We Serve
- Manufacturing site expansions
- Biotech and pharmaceutical companies
- Medical device companies
- Clinical-stage startups
- GxP software vendors
- AI-enabled platforms
- Organizations moving from paper to digital processes
- Organizations building modern data architectures
- Companies implementing AI analytics within regulated processes
Our Consulting Philosophy
We believe the next generation of consulting combines deep expertise with purpose-built technology. Not just more billable hours.
By combining experienced consultants with purpose-built technology, we help clients deliver projects more efficiently while maintaining the quality and compliance expected in regulated life sciences.
There is no one-size-fits-all approach. We remain flexible and adapt our approach to each client’s needs and requirements for client engagements.
#RootingForYou
Assurea has launched a campaign called #RootingForYou to support and inspire women who drive innovation.
Our Latest Blogs
September 20, 2026
From Paper to Digital in Pharma: A Practical Guide to Implementing LIMS, MES and eQMS
Moving from paper to digital sounds simple. Replace paper records with a digital system. In practice, there is much more to it. A laboratory may replace paper worksheets with a Laboratory Information Management System (LIMS). Manufacturing may move from paper batch records to an MES or electronic batch record (eBR). Quality may move deviations, CAPAs
September 17, 2026
What Can AI Analyze in Biopharma Manufacturing? 5 Practical Manufacturing and MSAT Use Cases
How AI powered analysis can help manufacturing and MSAT teams understand batch performance, yield, quality, investigations and technology transfer using data they already have Biopharma manufacturing teams already collect a lot of data. Batch records. Process parameters. In-process testing. Yield and recovery data. QC results. Deviations. Development reports. Tech transfer documents. The challenge is often
September 10, 2026
Case Study: Using Manufacturing Intelligence to Improve AAV Batch Performance
How historical AAV manufacturing data can uncover process optimization opportunities and help Process Development and MSAT focus their investigations AAV manufacturing generates large amounts of data across manufacturing systems, process historians, batch records, in-process testing and QC laboratories. But the data is often reviewed one batch or one system at a time. That makes it
September 3, 2026
Biotech Data Modernization in Practice: Building a Connected View of Biotech Operations
A growing biotech company wanted to answer a practical manufacturing question: Why are some batches taking longer than others? The information needed to investigate the question already existed. Manufacturing information was in the Manufacturing Execution System (MES). Process conditions were captured by a historian. Laboratory results were in the Laboratory Information Management System (LIMS). Quality
August 27, 2026
Data Modernization in Life Sciences: A Practical Roadmap for Pharma and Biotech
A biotech company may already have the data it needs to answer an important question. The problem is that the answer may be spread across five different systems. Consider one batch. The MES knows what happened during execution. The historian captures process conditions. LIMS contains laboratory results. The eQMS holds deviations and investigations. ERP contains
August 25, 2026
Assurea × Seeq Corporation: A New Partnership for GxP-Regulated Analytics
We’re excited to announce a new partnership between Assurea and Seeq to help pharma and biotech organizations adopt Seeq for Pharma within GxP-regulated environments. Assurea will serve as the implementation and validation partner for Seeq. As part of the partnership, Assurea has developed a validation package for Seeq that combines Assurea’s expertise in CSV and
August 24, 2026
What Oversight Drift Looks Like in Modern Pharma Digital Systems
In pharma and biotech, digital systems rarely stay the same after they go live. Workflows change, users increase, integrations are added, suppliers release updates, and the system becomes part of a larger operational environment. The real challenge is that oversight does not always evolve at the same pace. A system may still be validated, documented,
August 23, 2026
Case Study: Using AI Analytics to Transform GxP Periodic Reviews
27 periodic reviews. 650+ documents analyzed. One clear view of system health. Periodic reviews are intended to answer a relatively simple question: is this GxP system or piece of computerized equipment still operating in a controlled and appropriately validated or qualified state? Getting to that answer is rarely simple. A reviewer may need to look
August 22, 2026
Assurea × Runtime Verification: A New Partnership for Medical Device Software Assurance
We’re excited to announce a new partnership between Assurea and Runtime Verification! As software becomes increasingly critical to medical devices, SaMD, and artificial organs, companies need stronger ways to demonstrate that their software is safe, reliable, and ready for use in a regulated environment. This partnership brings together two complementary strengths. Runtime Verification brings deep
August 21, 2026
SaaS and Cloud Validation in Life Sciences: What Makes It Different and What Inspectors Really Ask
SaaS and cloud validation is different because the regulated company no longer controls the full technical stack, but it still owns intended use, oversight, data integrity, access, and compliance. That is where many teams misunderstand the real validation challenge. When a system is vendor-hosted, the validation work does not go away. It shifts. Instead of
August 19, 2026
How to Audit IT Infrastructure in GxP Environments
Auditing IT infrastructure in a GxP environment means checking whether the technical foundation behind regulated systems is controlled, supportable, and appropriate for its intended use. The audit should not stop at servers or network diagrams. It should test whether access, changes, backups, monitoring, and supporting services are managed in a way that protects system reliability
August 17, 2026
Contract & SLA Checklist for SaaS and AI Vendors in Pharma GxP Environments
Pharma companies cannot rely on standard commercial SaaS contracts alone when regulated systems, GxP data, or AI-enabled workflows are involved. In regulated environments, contracts and SLAs help define operational oversight expectations that support validation, data integrity, cybersecurity, supplier governance, and inspection readiness. Most commercial agreements are designed around uptime and commercial liability. Pharma and biotech
August 15, 2026
Preparing for Your First Digital System Implementation: A Practical Guide for Growing Biotech Companies
For a growing biotech company, implementing the first major digital system is an important milestone. Paper records, spreadsheets, shared drives, and disconnected tools that worked during early growth may no longer support increasing operational complexity, regulatory expectations, or future scale. The natural response is often to start evaluating software. But selecting an eQMS, LIMS, LMS,
August 5, 2026
AI Manufacturing Intelligence for Technology Transfer: Reducing Manual Master Batch Record Reviews
How AI-powered document analytics helps manufacturing teams compare complex documentation, identify process differences, and accelerate technology transfer while keeping GMP decisions under human oversight. Technology Transfer Is Still a Documentation-Intensive Process Successful technology transfer is about far more than moving a manufacturing process from one facility to another. It requires ensuring that manufacturing knowledge is
July 29, 2026
Validation of Veeva Vault Quality for a Global CDMO
How Assurea validated a U.S. deployment of Veeva Vault Quality and established a reusable validation framework for future global site rollouts. Project Overview When a global Contract Development and Manufacturing Organization (CDMO) selected Veeva Vault Quality to standardize its quality management processes, the first deployment was planned for a U.S. manufacturing site located on the
July 21, 2026
Reducing Post-Acquisition QMS Integration Effort with AI
How Assurea helped a biotechnology company assess and align site vs global QMS following an acquisition using AI-assisted analytics and expert quality review. Project Overview Following the acquisition of a biotechnology company, our client needed to understand how the acquired site’s Quality Management System (QMS) aligned with its global quality framework before beginning integration activities.
June 4, 2026
Who Owns What in SaaS Validation? Vendor vs Regulated Company Responsibilities
Many life sciences organizations commonly ask this question when implementing a SaaS platform: “If the vendor already validated the system, what do we still need to do?” The answer is straightforward. The vendor is responsible for the platform it develops, operates, and maintains. The regulated company remains responsible for how that platform is configured, governed,
May 28, 2026
How to Define Intended Use for AI and SaaS Tools in Pharma
Defining intended use is one of the most important steps in validating AI and SaaS tools in regulated pharma and biotech environments. The intended use statement establishes validation scope, testing strategy, risk classification, supplier oversight expectations, and procedural controls. For AI systems, this is often more difficult than traditional software because operational usage can evolve
April 9, 2026
AI Governance Frameworks That Work for Pharma
An AI governance framework for pharma works only when it goes beyond policy. It needs to connect each AI use case to a clear intended use, a defined risk tier, required controls, and ongoing monitoring. That is what makes the framework usable in practice and defensible in audit. If those links are missing, the framework
December 4, 2025
Validating Interfaces & Data Flows: Essential for Digital Validation in Life Sciences
In today’s digital biotech environment, labs and manufacturing sites rely on a complex network of interconnected systems: LIMS, QMS, MES, ERP, CDS, eBMRs, data historians, and analytics platforms. While each system may be validated independently, the movement of data between them is where the highest risk now lives. Regulators increasingly expect organizations to demonstrate end-to-end